AU2011310109B2 - Eph receptor expression in tumor stem cells - Google Patents

Eph receptor expression in tumor stem cells Download PDF

Info

Publication number
AU2011310109B2
AU2011310109B2 AU2011310109A AU2011310109A AU2011310109B2 AU 2011310109 B2 AU2011310109 B2 AU 2011310109B2 AU 2011310109 A AU2011310109 A AU 2011310109A AU 2011310109 A AU2011310109 A AU 2011310109A AU 2011310109 B2 AU2011310109 B2 AU 2011310109B2
Authority
AU
Australia
Prior art keywords
cells
gbm
epha2
ephrinal
cscs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011310109A
Other languages
English (en)
Other versions
AU2011310109A1 (en
Inventor
Elena Binda
Angelo Luigi Vescovi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STEMGEN SpA
Original Assignee
STEMGEN SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STEMGEN SpA filed Critical STEMGEN SpA
Publication of AU2011310109A1 publication Critical patent/AU2011310109A1/en
Application granted granted Critical
Publication of AU2011310109B2 publication Critical patent/AU2011310109B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2011310109A 2010-10-01 2011-09-30 Eph receptor expression in tumor stem cells Active AU2011310109B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10185930.4 2010-10-01
EP10185930A EP2446895A1 (en) 2010-10-01 2010-10-01 EPH receptor expression in tumor stem cells
PCT/EP2011/067114 WO2012042021A1 (en) 2010-10-01 2011-09-30 Eph receptor expression in tumor stem cells

Publications (2)

Publication Number Publication Date
AU2011310109A1 AU2011310109A1 (en) 2013-05-02
AU2011310109B2 true AU2011310109B2 (en) 2014-11-20

Family

ID=43856109

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011310109A Active AU2011310109B2 (en) 2010-10-01 2011-09-30 Eph receptor expression in tumor stem cells

Country Status (11)

Country Link
US (1) US9078857B2 (enExample)
EP (2) EP2446895A1 (enExample)
JP (4) JP2013540117A (enExample)
KR (2) KR20130095286A (enExample)
AU (1) AU2011310109B2 (enExample)
CA (1) CA2813101C (enExample)
DK (1) DK2621513T3 (enExample)
ES (1) ES2616444T3 (enExample)
NZ (1) NZ609594A (enExample)
PL (1) PL2621513T3 (enExample)
WO (1) WO2012042021A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ611428A (en) 2010-12-08 2015-07-31 Stemcentrx Inc Novel modulators and methods of use
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
EP2733206A1 (en) * 2012-11-19 2014-05-21 Naroa LLC Method for the isolation for mammalian stem cells using EphA2 and uses thereof
JP2016540826A (ja) 2013-11-04 2016-12-28 ファイザー・インク 抗ｅｆｎａ４抗体−薬物コンジュゲート
RU2708075C2 (ru) 2014-04-30 2019-12-04 Пфайзер Инк. Конъюгаты анти-ртк7 антитело-лекарственное средство
WO2016092378A1 (en) * 2014-12-10 2016-06-16 Angelo Luigi Vescovi Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors
KR20180016391A (ko) 2015-05-08 2018-02-14 플로우조, 엘엘시 데이터 발견 노드
US11174484B2 (en) 2015-11-10 2021-11-16 B. G. Negev Technologies And Applications Ltd., At Ben- Gurion University Means and methods for reducing tumorigenicity of cancer stem cells
EP4129311A4 (en) * 2020-03-31 2024-06-12 Keio University Therapeutic agent using genome-edited pluripotent stem cell
WO2026022122A1 (en) * 2024-07-23 2026-01-29 Eos Research Sa Checkpoint inhibitors in the treatment of glioblastoma multiforme

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123371A1 (en) * 2006-03-08 2009-05-14 Wake Forest University Health Sciences Molecular signature of cancer
US20100183618A1 (en) * 2007-08-30 2010-07-22 Daiichi Sankyo Company, Limited Anti-epha2 antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1682173A4 (en) * 2003-10-15 2007-10-31 Medimmune Inc EPHA2 VACCINE ON LISTERIA BASE
EP1778726A4 (en) * 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123371A1 (en) * 2006-03-08 2009-05-14 Wake Forest University Health Sciences Molecular signature of cancer
US20100183618A1 (en) * 2007-08-30 2010-07-22 Daiichi Sankyo Company, Limited Anti-epha2 antibody

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PASQUALE E B: NATURE (MARCH 2010), Vol 10, pages 165-180 *
WYKOSKY J et al: MOLECULAR CANCER RESEARCH. vol 3. no. 10. 1 October 2005 pages 541-551. *
WYKOSKY J et al: MOLECULAR CANCER THERAPEUTICS DEC 2007 vol, 6. no. pages 3208-3218. *

Also Published As

Publication number Publication date
JP6523910B2 (ja) 2019-06-05
DK2621513T3 (en) 2017-03-06
AU2011310109A1 (en) 2013-05-02
EP2621513A1 (en) 2013-08-07
NZ609594A (en) 2015-01-30
CA2813101A1 (en) 2012-04-05
PL2621513T3 (pl) 2017-06-30
EP2446895A1 (en) 2012-05-02
KR20160027106A (ko) 2016-03-09
JP2016094391A (ja) 2016-05-26
ES2616444T3 (es) 2017-06-13
WO2012042021A1 (en) 2012-04-05
US20120083454A1 (en) 2012-04-05
JP2020037579A (ja) 2020-03-12
JP2013540117A (ja) 2013-10-31
KR20130095286A (ko) 2013-08-27
US9078857B2 (en) 2015-07-14
JP2018048151A (ja) 2018-03-29
JP6618968B2 (ja) 2019-12-11
KR101719966B1 (ko) 2017-03-24
EP2621513B1 (en) 2016-12-28
CA2813101C (en) 2018-10-30

Similar Documents

Publication Publication Date Title
AU2011310109B2 (en) Eph receptor expression in tumor stem cells
Uhl et al. SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo
Barrett et al. NOX2 deficiency alters macrophage phenotype through an IL-10/STAT3 dependent mechanism: implications for traumatic brain injury
JP2021183629A (ja) 急性中枢神経系損傷疾患におけるヘキソキナーゼ２特異的阻害剤の応用
JP5891068B2 (ja) Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制
Atherton et al. Sympathetic modulation of tumor necrosis factor alpha-induced nociception in the presence of oral squamous cell carcinoma
US20080260644A1 (en) Chloride transport upregulation for the treatment of traumatic brain injury
Fang et al. Enhanced cell growth and tumorigenicity of rat glioma cells by stable expression of human CD133 through multiple molecular actions
CN114606323B (zh) 一种识别胃癌干细胞的标志物lgsn作为胃癌诊断和治疗靶标的应用
US20230190718A1 (en) Methods for the treatment of pancreatitis and prevention of pancreatic cancer
US20150352114A1 (en) MITOTIC KINESIN Eg5 INHIBITING ANTICANCER AGENTS
KR20200017495A (ko) Nk-92 세포 및 il-15 효능제의 조합 요법
KR20240052739A (ko) 급성 골수성 백혈병 치료를 위한 wnt5a
Joshi Hypoxic Regulation of Angiotensin-Converting Enzyme 2 and Mas Receptor in Hematopoietic Stem/Progenitor Cells: A Translational Study
CN115058518A (zh) Otub1基因、其检测试剂和抑制剂的应用
CN113144170A (zh) 肽及其在调节巨核细胞分化、治疗血小板相关疾病中的应用
WO2002084284A2 (en) Diagnosis and treatment of cancer:ii
Koodie Effects of chronic morphine treatment on tumor angiogenesis and growth
남서희 Novel functions of lysyl-tRNA synthetase in invasive dissemination of colon cancer cells in 3D microenvironment
Ma Mechanisms of Brain Edema Formation in Mouse Models of Intracerebral Hemorrhage
Lee Molecular Action of a Potential Tumor Suppression in Mammary Carcinogenesis
Gitto Novel Cytokine Signaling and Molecular Therapeutic Strategy in Pancreatic Cancer
SDA THE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 MONOCLONAL ANTIBODY D16F7 INHIBITS GLIOMA GROWTH AND ANGIOGENESIS IN VIVO
Walker The role of stromal cell-derived factor-1 in cell mobilization, cell homing, and neovascularization following stroke
Praetorius The regulation of RANK and RANKL mRNA expression through activation of the JAK2/STAT5a pathway in human breast cancer cell lines©

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)